Tags

Type your tag names separated by a space and hit enter

[Treatment of polycystic ovary syndrome and related infertility with clomiphene resistance by compound cyproterone acetate].
Zhonghua Fu Chan Ke Za Zhi. 1999 Sep; 34(9):528-32.ZF

Abstract

OBJECTIVE

To assess the efficacy and safety of compound cyproterone acetate (CPA Co, or Diane-35) in the treatment of polycystic ovary syndrome (PCOS) and to explore its potential role in improving the outcome of ovulation induction in clomiphene (CC) resistant cases.

METHODS

Twenty-nine proven PCOS patients were enrolled. Seventeen out of them, including 16 who were resistant to CC, had anovulatory infertility. CPA Co was given for 4-6 cycles. Serum luteinizing hormone(LH), follicle stimulating hormone(FSH), estradiol(E2), testosterone(T), androstenedione(A), dehydroepiandrosterone (Ds), sex hormone binding globvlin (SHBG), insulin concentrations, total cholesterol, triglycerides(TG), high density lipoprotein-cholesterol(HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein A, apolipoprotein B and transvaginal pelvic ultrasonography were determined before, 2-3 cycles and 4-6 cycles after treatment. After stopping the drug, CC or human menopausal gonadotropin were re-administered in 12 patients (22 cycles) and 5 cases (6 cycles) respectively for induction of ovulation.

RESULTS

All patients had regular uterine bleeding during CPA Co therapy. Acne improved in 8 cases. Hirsute score didn't decrease significantly. Serum LH, FSH, E2, A, T, Ds concentrations decreased significantly (P < 0.05-0.01), while SHBG levels increased by 5.1 times after treatment. Meanwhile, bilateral ovarian volumes shrunk and follicle numbers decreased significantly (P < 0.05-0.01). Serum insulin levels did not change significantly. As to the lipid profile, the most striking change was 55.1% increase of HDL-C and 23.0% decrease of LDL-C, although TG also increased by 36.2%. 58.6% of patients had mild and transient adverse effects. Serum alanine transaminase increased in 3 cases. After stopping treatment, CC induced 5.3% (by cases) or 45.4% (by cycles) ovulation rate and 2 pregnancies achieved in 12 CC resistant patients.

CONCLUSION

CPA Co has antiandrogenic effects on PCOS patients clinically, biochemically and in ovarian morphology. Pretreatment of CPA Co may play a role in improving the outcome of ovulation induction in CC resistant cases.

Authors+Show Affiliations

Peking Union Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

11360636

Citation

Tao, Y, et al. "[Treatment of Polycystic Ovary Syndrome and Related Infertility With Clomiphene Resistance By Compound Cyproterone Acetate]." Zhonghua Fu Chan Ke Za Zhi, vol. 34, no. 9, 1999, pp. 528-32.
Tao Y, Dai Q, Zhang D. [Treatment of polycystic ovary syndrome and related infertility with clomiphene resistance by compound cyproterone acetate]. Zhonghua Fu Chan Ke Za Zhi. 1999;34(9):528-32.
Tao, Y., Dai, Q., & Zhang, D. (1999). [Treatment of polycystic ovary syndrome and related infertility with clomiphene resistance by compound cyproterone acetate]. Zhonghua Fu Chan Ke Za Zhi, 34(9), 528-32.
Tao Y, Dai Q, Zhang D. [Treatment of Polycystic Ovary Syndrome and Related Infertility With Clomiphene Resistance By Compound Cyproterone Acetate]. Zhonghua Fu Chan Ke Za Zhi. 1999;34(9):528-32. PubMed PMID: 11360636.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of polycystic ovary syndrome and related infertility with clomiphene resistance by compound cyproterone acetate]. AU - Tao,Y, AU - Dai,Q, AU - Zhang,D, PY - 2001/5/22/pubmed PY - 2001/6/8/medline PY - 2001/5/22/entrez SP - 528 EP - 32 JF - Zhonghua fu chan ke za zhi JO - Zhonghua Fu Chan Ke Za Zhi VL - 34 IS - 9 N2 - OBJECTIVE: To assess the efficacy and safety of compound cyproterone acetate (CPA Co, or Diane-35) in the treatment of polycystic ovary syndrome (PCOS) and to explore its potential role in improving the outcome of ovulation induction in clomiphene (CC) resistant cases. METHODS: Twenty-nine proven PCOS patients were enrolled. Seventeen out of them, including 16 who were resistant to CC, had anovulatory infertility. CPA Co was given for 4-6 cycles. Serum luteinizing hormone(LH), follicle stimulating hormone(FSH), estradiol(E2), testosterone(T), androstenedione(A), dehydroepiandrosterone (Ds), sex hormone binding globvlin (SHBG), insulin concentrations, total cholesterol, triglycerides(TG), high density lipoprotein-cholesterol(HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein A, apolipoprotein B and transvaginal pelvic ultrasonography were determined before, 2-3 cycles and 4-6 cycles after treatment. After stopping the drug, CC or human menopausal gonadotropin were re-administered in 12 patients (22 cycles) and 5 cases (6 cycles) respectively for induction of ovulation. RESULTS: All patients had regular uterine bleeding during CPA Co therapy. Acne improved in 8 cases. Hirsute score didn't decrease significantly. Serum LH, FSH, E2, A, T, Ds concentrations decreased significantly (P < 0.05-0.01), while SHBG levels increased by 5.1 times after treatment. Meanwhile, bilateral ovarian volumes shrunk and follicle numbers decreased significantly (P < 0.05-0.01). Serum insulin levels did not change significantly. As to the lipid profile, the most striking change was 55.1% increase of HDL-C and 23.0% decrease of LDL-C, although TG also increased by 36.2%. 58.6% of patients had mild and transient adverse effects. Serum alanine transaminase increased in 3 cases. After stopping treatment, CC induced 5.3% (by cases) or 45.4% (by cycles) ovulation rate and 2 pregnancies achieved in 12 CC resistant patients. CONCLUSION: CPA Co has antiandrogenic effects on PCOS patients clinically, biochemically and in ovarian morphology. Pretreatment of CPA Co may play a role in improving the outcome of ovulation induction in CC resistant cases. SN - 0529-567X UR - https://www.unboundmedicine.com/medline/citation/11360636/[Treatment_of_polycystic_ovary_syndrome_and_related_infertility_with_clomiphene_resistance_by_compound_cyproterone_acetate]_ L2 - http://www.diseaseinfosearch.org/result/9713 DB - PRIME DP - Unbound Medicine ER -